Loading clinical trials...
Loading clinical trials...
Nasolacrimal duct obstruction (NLDO) can manifest as epiphora or recurrent infections with mucopurulent discharge and may even cause social embarrassment. Dacryoendoscopic-assisted laser dacryoplasty ...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Tianjin Eye Hospital
NCT05999630 · Nasolacrimal Duct Obstruction, Thyroid Cancer
NCT07154121 · Primary Acquired Nasolacrimal Duct Obstruction
NCT06530264 · Acquired Nasolacrimal Duct Obstruction
NCT04837534 · CNLDO - Congenital Nasolacrimal Duct Obstruction, Amblyopia, and more
NCT04122300 · Congenita Nasolacrimal Duct Obstruction, Preterm Neonates, and more
Tianjin Eye Hospital
Tianjin, Tianjin Municipality
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions